Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Eigenbrot

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Nature Chemical Biology|August 2, 2016
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibitionAaron Boudreau, Hans E Purkey, Anna Hitz, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor InhibitorBryan K Chan, Emily J Hanan, Krista K Bowman, et al.
ACS Medicinal Chemistry Letters|October 25, 2016
Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in MiceHans E Purkey, Kirk Robarge, Jinhua Chen, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Journal of Medicinal Chemistry|May 15, 2013
Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitorsJun Liang, Anne van Abbema, Mercedesz Balazs, et al.
Nature|July 30, 2010
Diverse somatic mutation patterns and pathway alterations in human cancersZhengyan Kan, Bijay S Jaiswal, Jeremy Stinson, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Journal of Medicinal Chemistry|June 16, 2012
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Mark Zak, Rohan Mendonca, Mercedesz Balazs, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Nature Chemical Biology|August 2, 2016
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibitionAaron Boudreau, Hans E Purkey, Anna Hitz, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor InhibitorBryan K Chan, Emily J Hanan, Krista K Bowman, et al.
ACS Medicinal Chemistry Letters|October 25, 2016
Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in MiceHans E Purkey, Kirk Robarge, Jinhua Chen, et al.
Journal of Medicinal Chemistry|December 12, 2017
Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease SpecificityBinQing Wei, Janet Gunzner-Toste, Hui Yao, et al.
Journal of Medicinal Chemistry|May 15, 2013
Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitorsJun Liang, Anne van Abbema, Mercedesz Balazs, et al.
Nature|July 30, 2010
Diverse somatic mutation patterns and pathway alterations in human cancersZhengyan Kan, Bijay S Jaiswal, Jeremy Stinson, et al.
ACS Medicinal Chemistry Letters|June 20, 2017
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike PropertiesXiaojing Wang, James Barbosa, Peter Blomgren, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Journal of Medicinal Chemistry|June 16, 2012
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2Mark Zak, Rohan Mendonca, Mercedesz Balazs, et al.
Pageof 11